Huntington’s Disease (HD): Degeneration of Select Nuclei, Widespread Occurrence of Neuronal Nuclear and Axonal Inclusions in the Brainstem

Udo Rüb; Matthias Hentschel; Katharina Stratmann; Ewout Brunt; Helmut Heinsen; Kay Seidel; Mohamed Bouzrou; Georg Auburger; Henry Paulson; Jean-Paul Vonsattel; Herwig Lange; Horst-Werner Korf; Wilfred den Dunnen

1 Dr. Senckenberg Chronomedical Institute, Goethe-University, Frankfurt/Main, Germany.
2 Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.
3 Morphological Brain Research Unit, Psychiatric Clinic, Julius Maximilians University Würzburg, Würzburg, Germany.
4 Department of Neurology, Goethe-University, Frankfurt/Main, Germany.
5 Department of Neurology, University of Michigan, Ann Arbor, MI.
6 The New York Brain Bank/Taub Institute, The Presbyterian Hospital and Columbia University, New York, NY.
7 Chorea Center, Department of Neurology, University of Muenster, Münster Germany.
8 Department of Pathology and Medical Biology, University of Groningen, Groningen, The Netherlands.

Keywords
axonal inclusions, brainstem, Huntington’s disease, neurodegeneration, pathoanatomy, polyglutamine diseases.

Abstract
Huntington’s disease (HD) is a progressive polyglutamine disease that leads to a severe striatal and layer-specific neuronal loss in the cerebral neo- and allocortex. As some of the clinical symptoms (e.g., oculomotor dysfunctions) suggested a degeneration of select brainstem nuclei, we performed a systematic investigation of the brainstem of eight clinically diagnosed and genetically confirmed HD patients. This post-mortem investigation revealed a consistent neuronal loss in the substantia nigra, pontine nuclei, reticulotegmental nucleus of the pons, superior and inferior olives, in the area of the excitatory burst neurons for horizontal saccades, raphe interpositus nucleus and vestibular nuclei. Immunoreactive intranuclear neuronal inclusions were present in all degenerated and apparently spared brainstem nuclei and immunoreactive axonal inclusions were observed in all brainstem fiber tracts of the HD patients. Degeneration of brainstem nuclei can account for a number of less well-understood clinical HD symptoms (i.e., cerebellar, oculomotor and vestibular symptoms), while the formation of axonal aggregates may represent a crucial event in the cascades of pathological events leading to neurodegeneration in HD.

INTRODUCTION
Huntington’s disease (HD) is an autosomal dominantly inherited, progressive and currently untreatable polyglutamine or CAG-repeat disease (10, 16, 17, 24, 31, 46, 49, 56, 62, 63, 72, 76, 81–83). Clinically, HD presents with somatomotor (i.e., chorea, bradykinesia, dystonia, rigidity, dysarthria, dysphagia), oculomotor and psychiatric symptoms, cognitive decline and often with a severe weight loss (5, 16, 25–27, 34, 42, 44, 49, 51, 62, 63, 72, 76, 83, 85, 86). Macroscopic brain alterations in HD commonly include atrophy of all cerebral lobes, reduction of cerebral white matter, atrophy of the striatum and enlarged lateral ventricles (3, 5, 15, 25–27, 39–41, 62, 63, 72, 73, 81–83). Although the degenerative process of the HD brain is widespread, to date, the severe neuronal loss in the striatum and the layer-specific neurodegeneration in distinct areas of the cerebral neo- and allocortex is considered as generally the hallmark of the neuropathological changes (3, 5, 15, 25–27, 31, 35, 39–41, 47, 52, 62, 63, 72, 73, 81–83). Based on the worsening and topographical spread of the degenerative process of the striatum, a neuropathological HD grading system has been developed (81–83). Some of the unexpected HD symptoms (e.g., oculomotor dysfunctions) as well as the previous, but widely forgotten assumptions have suggested additional degeneration of select brainstem nuclei...
in HD and pointed to the necessity of detailed brainstem studies in HD (5, 32, 34, 41, 42, 44, 45, 62, 64, 81–83).

Located on chromosome 4p16.3, the HD gene harbors meiotically unstable CAG-repeats which encode the pathogenic mutated protein huntingtin (16, 17, 31, 46, 49, 51, 72, 76, 81, 85, 86). In symptomatic HD patients and asymptomatic gene carriers, these CAG-repeats are expanded and lead to a polyglutamine expansion in mutant huntingtin. The normal physiological CAG-repeat sequences comprise six to 35 CAG triplets, whereby sequences of 28 and more already behave instable during meiosis and may be prone to potentially symptomatic mutations. CAG-repeat sequences longer than 35 are considered pathologically expanded, 36 to 40 CAG-repeats lead to an incomplete penetrance and expansions of 41 or more CAG-repeats to the fully developed clinical picture of HD (16, 31, 46, 49, 51, 66, 72, 76, 81, 85, 86).

The subcellular neuronal localization of huntingtin is complex and dynamic. It is normally associated with the Golgi complex and mitochondria, localizes to microtubules and synaptic vesicles, is believed to play an important role in embryogenic development, gene transcription, regulation of axonal transport mechanisms, anterograde and retrograde trafficking of vesicles and organelles, as well as in transport of signaling and trophic factors (1, 17, 21, 31, 46, 66, 79, 81). As with other polyglutamine disease proteins, mutant huntingtin tends to aggregate into insoluble neuronal intranuclear inclusions (NI), which also contain components of the intracellular machinery responsible for protein handling and degrading of misfolded proteins (eg, ubiquitin, proteasome subunits, chaperones) (2, 10, 14, 17, 19, 31, 36, 46–48, 65, 66, 73, 74, 77, 80, 81, 85, 86). Although these NI may be present in the cerebral cortex and striatum of HD patients, their pathogenic role in the demise of neurons still is uncertain (1, 2, 14, 17, 19, 22, 31, 36, 47, 48, 56, 72–74, 80, 81). Recently, we described the brain distribution, neuronal localization and composition of neuronal protein aggregates in another polyglutamine disease, the spinocerebellar ataxia type 3 (SCA3 or Machado-Joseph disease) (69). Inspired by the enigmatic pathogenic role of NI in HD and our recent SCA3 findings, we performed a systematic immunohistochemical study of the brainstem of eight clinically diagnosed and genetically confirmed HD patients and analyzed the presence, distribution and localization of NI and neuropil aggregates in brainstem nuclei or fiber tracts. The results of these analyses were correlated with the pathoanatomical findings obtained upon investigation of unconventional thick tissue sections through the brainstem of these HD patients.

**PATIENTS AND METHODS**

**Patients**

We investigated the brainstem of eight clinically diagnosed and genetically confirmed HD patients (age at death: 67.3 ± 11.3 years; Tables 1 and 2) and of 14 control individuals without histories of neurological or psychiatric diseases in their medical records and no diagnostic abnormalities recognized on neuropathological examination of their brain (eight females, six males; age at death: 61.6 ± 16.5 years) (Table 3). All of our HD patients suffered from involuntary choreatic movements and progressive cognitive decline (patients 1–8; Table 1). Seven showed a severe weight loss (patients 1, 2, 4–8; Table 1), five had dysphagia (patients 1, 2, 4, 5, 7, 8).

<table>
<thead>
<tr>
<th>HD Patient</th>
<th>Age</th>
<th>Gender</th>
<th>CAG</th>
<th>TI</th>
<th>Vonsattel grade</th>
<th>Onset of initial HD symptoms</th>
<th>Initial HD symptoms</th>
<th>Duration of HD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>51</td>
<td>M</td>
<td>49</td>
<td>60</td>
<td>4</td>
<td>33</td>
<td>Personality changes</td>
<td>18</td>
</tr>
<tr>
<td>2</td>
<td>61</td>
<td>F</td>
<td>45</td>
<td>6</td>
<td>3</td>
<td>35</td>
<td>Chorea</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>M</td>
<td>41</td>
<td>3</td>
<td>2</td>
<td>55</td>
<td>Chorea</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>65</td>
<td>M</td>
<td>45</td>
<td>36</td>
<td>4</td>
<td>53</td>
<td>Ataxia</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>68</td>
<td>F</td>
<td>46</td>
<td>18</td>
<td>3</td>
<td>40</td>
<td>Cognitive decline</td>
<td>28</td>
</tr>
<tr>
<td>6</td>
<td>68</td>
<td>M</td>
<td>40</td>
<td>29</td>
<td>3</td>
<td>60</td>
<td>Cognitive decline</td>
<td>8</td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>F</td>
<td>44</td>
<td>4</td>
<td>2</td>
<td>50</td>
<td>Chorea</td>
<td>20</td>
</tr>
<tr>
<td>8</td>
<td>91</td>
<td>M</td>
<td>42</td>
<td>72</td>
<td>5</td>
<td>55</td>
<td>Chorea</td>
<td>36</td>
</tr>
</tbody>
</table>

**Table 1.** Overview of the Huntington’s disease (HD) patients studied.

Abbreviations: CAG = number of expanded CAG-repeats in the mutated HD allele; F = female; HD = Huntington’s disease; M = male; TI = time interval between the last neurological investigation and death.

<table>
<thead>
<tr>
<th>HD Patient</th>
<th>Age at death (years)</th>
<th>Gender</th>
<th>Number of expanded CAG-repeats in the mutated HD allele</th>
<th>Time interval between the last neurological investigation and death (TI, months)</th>
<th>Vonsattel grade of striatal atrophy</th>
<th>Age at onset of initial HD symptoms (years)</th>
<th>Initial HD symptoms</th>
<th>Duration of HD (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>67.3 ± 11.3 years</td>
<td>M</td>
<td>49</td>
<td>60</td>
<td>4</td>
<td>33</td>
<td>Personality changes</td>
<td>18</td>
</tr>
<tr>
<td>2</td>
<td>67.3 ± 11.3 years</td>
<td>F</td>
<td>45</td>
<td>6</td>
<td>3</td>
<td>35</td>
<td>Chorea</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>67.3 ± 11.3 years</td>
<td>M</td>
<td>41</td>
<td>3</td>
<td>2</td>
<td>55</td>
<td>Chorea</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>67.3 ± 11.3 years</td>
<td>M</td>
<td>45</td>
<td>36</td>
<td>4</td>
<td>53</td>
<td>Ataxia</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>67.3 ± 11.3 years</td>
<td>F</td>
<td>46</td>
<td>18</td>
<td>3</td>
<td>40</td>
<td>Cognitive decline</td>
<td>28</td>
</tr>
<tr>
<td>6</td>
<td>67.3 ± 11.3 years</td>
<td>M</td>
<td>40</td>
<td>29</td>
<td>3</td>
<td>60</td>
<td>Cognitive decline</td>
<td>8</td>
</tr>
<tr>
<td>7</td>
<td>67.3 ± 11.3 years</td>
<td>F</td>
<td>44</td>
<td>4</td>
<td>2</td>
<td>50</td>
<td>Chorea</td>
<td>20</td>
</tr>
<tr>
<td>8</td>
<td>67.3 ± 11.3 years</td>
<td>M</td>
<td>42</td>
<td>72</td>
<td>5</td>
<td>55</td>
<td>Chorea</td>
<td>36</td>
</tr>
</tbody>
</table>
The pathoanatomical approach complements the routine neuropathological examination of thin brain tissue sections in the field of basic neuropathological research. Its application to unconventionally thick serial brain tissue sections allows the recognition of subtle pathological changes and reveals more detailed information with respect to the extent and severity of the pathological processes of neurodegenerative diseases (57, 59, 62, 64). Pathoanatomical examination of neuronal loss in the HD brainstems was performed twice by U. Rüb and its extent was scored as not discernible (−), marked (+) or severe (+++) (Table 4). The second assessment of neuronal loss was performed 6 months after the first one and blinded to its results.

Table 4. Distribution and extent of neuronal loss in the lower brainstem of Huntington’s disease (HD) patients. Abbreviations: EBR = area of the excitatory burst neurons for horizontal saccades; IO = inferior olive; LV = lateral vestibular nucleus; MV = medial vestibular nucleus; PCRT = parvocellular reticular nucleus; PN = pontine nuclei; RIP = raphe interpositus nucleus; RTTG = reticulotegmental nucleus of the pons; SNC = substantia nigra, compact part; SNR = substantia nigra, reticulate part; SO = superior olive; SUV = superior vestibular nucleus; VII = facial nucleus.

<table>
<thead>
<tr>
<th>Patient</th>
<th>SNC</th>
<th>SNR</th>
<th>PN</th>
<th>RTTG</th>
<th>SUV</th>
<th>EBR</th>
<th>RIP</th>
<th>SO</th>
<th>VII</th>
<th>PCRT</th>
<th>LV</th>
<th>MV</th>
<th>IO</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>–</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>2</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>3</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>4</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>5</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>6</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>7</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>8</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
</tbody>
</table>
In all HD patients and control individuals, the second set of serial brainstem tissue sections was immunolabeled with an antibody directed against the protein aggregation marker p62 (1:100, Santa Cruz, Dallas, TX, USA). The multifunctional protein p62 participates in the intracellular trafficking, aggregation and degradation of various neurodegenerative disease proteins and is known to bind to abnormal nuclear and/or cytoplasmic neuronal accumulations of the disease-specific proteins of various neurodegenerative diseases (35, 36, 67–69). Pretreatment for antigen retrieval before the application of the p62 antibody was performed with 10 mM citrate buffer (pH 6.0) at 90°C for 30 minutes. Positive immunoreactions were visualized with a 3,3-diaminobenzidine-tetra-HCl/H2O2 reaction (DAB, D5637 Sigma, Taufkirchen, Germany) resulting in a brown staining. The p62-immunolabeled tissue sections were counterstained for lipofuscin pigment (aldehydfuchsin) and Nissl material (Darrow red) (3, 4, 61–64) and used for the detection of NI bodies. The evaluation of NI in the HD brainstem nuclei was performed twice by U. Rüb and scored as follows: NI not detectable and this after confirmative, sequential assessments of a given brainstem nucleus (−), rare (+) or many (++). The second assessment of the presence of NI was performed 6 months after the first investigation and blinded to the results of the first assessment.

In each instance the third set of serial brainstem tissue sections was immunostained for GFAP to reveal reactive astrocytes.

Double immunostaining procedures were performed to identify and examine the topographical and intra-axonal localization, as well as composition of neuropil aggregates. The AT270 antibody (1:4000, Thermo Scientific, Rockford, IL; USA), directed against the neuronal cytoskeletal protein tau was used as axonal marker (18, 71) and the anti-p62 antibody applied as marker for axonal aggregates in brainstem fiber tracts, and of brainstem neurodegeneration (78). The presence of p62-immunopositive axonal inclusions was semi-quantitatively assessed by U. Rüb and M. Hentschel and categorized as follows: axonal inclusions not detectable even after a time period of 3 minutes of careful investigation of a given fiber tract (−), or rare, or detectable after a time period of 3 minutes of examination (+), many (++)(Table 5). The assessments of U. Rüb and M. Hentschel were performed independently and blinded to the results of each other.

Double immunofluorescence was also applied to investigate the colocalization of the p62 shuttle protein with (i) the pathologically altered disease protein huntingtin harboring an elongated polyglutamin tract or (ii) ubiquitin in axonal aggregates. We applied the 1C2 antibody (1:3000, Millipore, Billerica, CA, USA) to confirm the presence of huntingtin with an expanded polyglutamine sequence of more than 37 repeats in the axonal aggregates and used an ubiquitin antibody (1:1000, Cell Signaling, Danvers, MA, USA) to investigate their additional association with the small degradation-related protein ubiquitin. Select brainstem tissue sections of all HD patients were (i) incubated with both the monoclonal mouse and polyclonal rabbit primary antibodies for 20 h at room temperature; (ii) followed by secondary incubation for 90 minutes with Alexa 488 (1:1000, Invitrogen, Carlsbad, CA, USA) and CY3 conjugated secondary antibodies (1:500, Jackson ImmunoResearch, West Grove, PA, USA); and (iii) treated for 10 minutes with 0.06% sudan-black for quenching of autofluorescence. The primary and secondary antibodies were applied simultaneously (69, 78). Antigen retrieval for p62/ubiquitin double immunostainings was performed as described above. Retrieval for 1C2/p62 was performed with Tris/HCl pH 9 at 90–05°C for 30 minutes, followed by incubation in 100% formic acid for 3 minutes at room temperature.

We investigated the reproducibility of the examination of the presence of NI, occurrence of axonal p62 immunoreactive aggregates in brainstem fiber tracts, and of brainstem neurodegeneration in the HD patients by means of inter-rater and intra-rater reliabilities and calculated the weighted kappa coefficient Kω. (BiAS for Windows, version 9.14, Epsilon, Darmstadt, Germany). In the case of disagreement of the investigators, the final assessment of neuronal loss, presence of NI and axonal aggregates was decided during a final consensus meeting. Kendall’s rank correlation coefficient τ (τ) was applied to examine the correlation between neuronal loss in brainstem nuclei of the HD patients and patient distribution Table 5. Distribution of p62-immunopositive protein aggregates in axons of brainstem fiber tracts of Huntington’s (HD) patients. Abbreviations: CCT = central tegmental tract; CU = cuneate fascicle; DST = dorsal spinocerebellar tract; GR = gracile fascicle; ICP = inferior cerebellar peduncle; LL = lateral lemniscus; MCP = medial cerebellar peduncle; ML = medial lemniscus; MLF = medial longitudinal fascicle; NSP = nigrostriatal pathway; OCT = olivocerebellar fibers; PCF = pontocerebellar fibers; PYR = pyramidal tract; SCP = superior cerebellar peduncle; SOL = solitary tract; SPV = spinal trigeminal tract; TZ = trapezoid body; VST = ventral spinocerebellar tract; III = oculomotor nerve; IV = trochlear nerve; V = trigeminal nerve; VI = abducens nerve; VII = facial nerve; VIII = vestibulococlear nerve; IX/X = vagal nerve; XII = hypoglossal nerve.

| Patient | III | IV | NSP | MLF | LL | ML | SCP | V | MCP | PF | VI | VII | TZ | CTT | VIII | ICP | PYR | SPV | IX/X | SOL | OCF | CU | GR | DST | VST | XII |
|---------|-----|----|-----|-----|----|----|-----|---|-----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 1       | +   | +   | ++  | +   | +   | ++ | +   | + | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | +   | +   | ++ | +   | ++ | ++ | ++ | +   |
| 2       | +   | +   | +   | +   | +   | + | +   | + | +   | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | ++ | ++ | ++ | ++ | ++ | +   |
| 3       | +   | +   | ++  | +   | +   | + | +   | + | +   | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | ++ | ++ | ++ | ++ | ++ | +   |
| 4       | +   | +   | +   | +   | +   | + | +   | + | +   | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | ++ | ++ | ++ | ++ | ++ | +   |
| 5       | +   | +   | +   | +   | +   | + | +   | + | +   | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | ++ | ++ | ++ | ++ | ++ | +   |
| 6       | +   | +   | +   | +   | +   | + | +   | + | +   | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | ++ | ++ | ++ | ++ | ++ | +   |
| 7       | +   | +   | ++  | +   | +   | + | +   | + | +   | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | ++ | ++ | ++ | ++ | ++ | +   |
| 8       | +   | +   | ++  | +   | +   | + | +   | + | +   | +   | +   | +   | ++ | ++ | ++ | +   | +   | +   | +   | +   | +   | ++ | ++ | ++ | ++ | ++ | +   |
the length of the CAG-repeats in the mutated HD allele, age of HD onset, duration of HD, age at death and the Vonsattel grade of striatal atrophy (BiAS for Windows, version 9.14, Epsilon). The \( \tau \) coefficient was also used to describe the correlation between the extent of neuronal loss in the brainstem nuclei of the HD patients and the presence of p62 immunoreactive axonal inclusions in associated brainstem fiber tracts (BiAS for Windows, version 9.14, Epsilon).

Examination of the HD and control brainstems was approved by the Ethical board of the Faculty of Medicine at the Goethe University of Frankfurt/Main.

RESULTS

The lower brainstem of all HD patients along with a flattened pons showed no macroscopic signs of degeneration (Figure 1).

In contrast to the routine neuropathological examination performed on thin tissue sections, our pathoanatomical study of thick tissue sections revealed neurodegeneration of select brainstem nuclei in all HD patients (Table 4).

A consistent neuronal loss was present in the dopaminergic compact part and GABAergic reticulate part of the substantia nigra, precerbellar pontine nuclei, reticulotegmental nucleus of the pons (Figure 2A,B), inferior olive (Figure 3E,F), in the premotor oculo-precerebellar pontine nuclei, reticulotegmental nucleus of the pons compact part and GABAergic reticulate part of the substantia nigra, nuclei in all HD patients (Table 4).

Calculation of Kendall’s rank correlation coefficient tau (\( \tau \)) revealed no significant correlation between neuronal loss in brainstem nuclei and the length of the CAG-repeats in the mutated HD allele, age of HD onset, duration of HD, age at death and Vonsattel grade of striatal atrophy (all \( P \)-values > 0.10). Calculation of the weighted kappa coefficient revealed a nearly perfect intrarater reliability for the semi-quantitative assessment of neuronal loss in the brainstem nuclei of the HD patients (\( K_w = 0.83; P < 0.0001 \)).

No p62 immunoreactive nuclear inclusions (NI) were detected within the brainstem of control brains. However, NI were found within the brainstem of the eight HD patients. They involved both the brainstem nuclei with or without documented neuronal loss. The nucleus of a few neurons had two or even three NI (Figure 4).

Calculation of the weighted kappa coefficient revealed a nearly perfect intrarater reliability for the semi-quantitative assessment of p62 immunoreactive NI in brainstem nuclei of the HD patients (\( K_w = 0.90; P < 0.0001 \)).

Unlike in the control individuals studied, p62 immunoreactive axonal inclusions were ubiquitous throughout the brainstem of all HD patients (pyramidal tract, all cerebellar peduncles, medial and lateral lemnisci, medial longitudinal fascicle, trapezoid body, pontocerebellar and olivocerebellar fibers, pontine reticular formation, spinocerebellar tracts, cuneate and gracile fascicles) (Figure 5; Table 5). Axonal inclusions were present in the axonal hillock (Figure 5B) or in more distal parts of the axon (Figure 5A,C–1,K,L,O,P) and in some instances occurred at multiple sites of an affected axon (Figure 5J,M,N). Their shape varied from round (Figure 5H,O), ovoid (Figure 5A,F,P), club-shaped (Figure 5B,E,K,L), irregular (Figure 5C,D,J,M), ramified (Figure 5N), to torpedo-like (Figure 5G,I). Their diameter was either nearly identical to that of the affected axon (Figure 5F,L,N) or larger than the normal axonal diameter (Figure 5A,G,E,G–I,K–M,O,P). Calculation of weighted kappa revealed a substantial interrater reliability for the semi-quantitative assessment of p62 immunoreactive axonal inclusions in brainstem fiber tracts (\( K_w = 0.74; P < 0.0001 \)).

In contrast to the control cases studied, GFAP immunopositive astrocytes were present in all degenerated and spared brainstem nuclei of all HD patients (data not shown).

Additional double immunostainings of brainstem tissue sections of our HD patients confirmed the presence of a protein with an expanded polyglutamine stretch (ie, detection of mutant huntingtin with the 1C2 antibody) in the p62-immunopositive axonal protein aggregates (Figure 6) and also demonstrated their ubiquitination (Figure 7).

DISCUSSION

Degeneration of the brainstem in HD

The degeneration of the brainstem and its possible clinical relevance in HD has been controversially discussed in neuropathological research for many decades (5, 32, 45, 52, 62, 82, 83). Neuropathological conjectures from years ago indicate that some brainstem nuclei may undergo neuronal loss in HD (ie, dopaminergic and GABAergic substantia nigra, auditory superior olive, lateral vestibular nucleus, precerbellar inferior olive), but these earlier findings have not been revisited or taken into account by current researchers. Thus, the involvement of the brainstem in HD is not among the established degenerative features of HD (5, 32, 41, 52, 82, 83). Our present pathoanatomical study, performed on serial thick tissue sections through the brainstem of eight
clinically diagnosed and genetically confirmed HD patients, confirms and extends the earlier assumptions regarding brainstem involvement in HD. Based on our findings, damage to the brainstem in HD proved to be more widespread than documented so far in the published literature and included additional nuclei of the precerebellar, vestibular, oculomotor and ingestion-related systems. As degeneration of brainstem nuclei did not correlate with the Vonsattel HD grade of striatal atrophy, it is likely that damage to these nuclei does not develop simultaneously with, but independently from the well-known pathognomonic lesions in the striatum. Taken together, damage to the brainstem again shows that neurodegeneration during HD is not restricted to the striatum and cerebral neo- and allocortex. We conclude that HD is a multisystem neurodegenerative disease (3, 5, 15, 25–27, 39–41, 73, 81–83) characterized by a distribution of brain damage that shows more overlap with that of the polyglutamine ataxias (eg, spinocerebellar ataxias types 1, 2, 3 and 7) than has been believed (43, 54, 57–61, 70).

**Clinicopathological correlation of brainstem degeneration in HD**

The human brainstem is integrated into various brain neurotransmitter systems, as well as into circuits subserving auditory,
precerebellar, ingestion-related, and oculomotor functions, and regulation of posture and balance (7, 9, 28, 29, 33, 58, 60, 64, 84). Although a wide spectrum of oculomotor symptoms typically emerge in HD patients (ie, slowed and saccadic smooth pursuits, reduced gain of the vestibulo-ocular reflex and optokinetic nystagmus, initiating deficits of saccades, slowing, restricted range or loss of horizontally and/or vertical saccades; impaired steady fixation) and may also occur in preclinical HD gene carriers (42, 44, 62), nearly all past attempts to decipher the morphological
counterparts of these oculomotor dysfunctions have failed (32, 45, 62). Progress in the field of the functional neuroanatomy of the human oculomotor networks made over the last two decades led to the identification and characterization of important premotor oculomotor brainstem nuclei. As a result, a detailed and reliable basis for precise structure-function relationships became available which enabled the establishment of clinicopathological correlations in various neurodegenerative diseases (7, 9, 29, 58, 60, 64, 64).

Figure 3. Neuronal loss in the pontomedullary junction and medulla oblongata in Huntington’s disease (HD). A. Horizontal section through the pontomedullary junction of a typical 54-year-old male control individual depicting the lateral (LV) and magnocellular portion of the medial (MV) vestibular nuclei (control individual 5; Table 3). B. Severe loss of LV and MV nerve cells of a 61-year-old female HD patient (CAG-repeats in the mutated HD allele: 45; age at HD onset: 35 years; duration of HD: 26 years; Vonsattel grade of striatal atrophy: 3; patient 2, Tables 1, 2 and 4). Arrow points to a remaining giant LV nerve cell. C. Horizontal section through the mid-pons of a representative 54-year-old male control individual depicting the auditory superior olive (SO) with its medial (MSO) and lateral subnuclei (LSO) as well as its periolivary group (SOP) (control individual 5; Table 3). D. SO neuronal loss of a 61-year-old female HD patient (CAG-repeats in the mutated HD allele: 45; age at HD onset: 35 years; duration of HD: 26 years; Vonsattel grade of striatal atrophy: 3; patient 2, Tables 1, 2 and 4) predominantly affecting the LSO and SOP. E. Horizontal section through the medulla oblongata a 84-year-old male control individual without any medical histories of neuropsychiatric diseases showing the inferior olive (IO) with its principal (IOP) and medial accessory subnuclei (IOM) (control individual 13; Table 3). F. Circumscribed severe neuronal loss in the IOP (asterisk) of an 91-year-old male HD patient (CAG-repeats in the mutated HD allele: 42; age at HD onset: 55 years; duration of HD: 36 years; Vonsattel grade of striatal atrophy: 2; patient 8; Tables 1, 2 and 4). Inset shows devastated area of the IOP (marked in F by an asterisk) with severe neuronal loss and the presence of extraneuronal lipofuscin deposits. Arrowheads point to remaining IOP nerve cells and arrows to extraneuronal lipofuscin deposits which can serve as reliable marker for neurodegeneration (A–F: aldehyde-fuchsin Darrow red staining; 100 μm PEG sections). Abbreviations: IO = inferior olive; IOM = inferior olive, medial accessory subnucleus; IOP = inferior olive, principal subnucleus; LSO = lateral superior olive; LV = lateral vestibular nucleus; MSO = medial superior olive; MV = medial vestibular nucleus, magnocellular portion; SO = superior olive; SOP = superior olive, periolivary group; TZ = trapezoid body; VII = facial nerve.
The raphe interpositus nucleus (RIP) (Figure 2E) was identified and described in non-human primates and in humans 25 years ago. This small nucleus at the midline of the pontomedullary junction is located between the rootlets of the abducens nerve. The horizontally oriented nerve cells of the RIP are linearly arranged in a narrow band of only two or three nerve cells and represent omnipause neurons that trigger the initiation of vertical and horizontal saccades (7, 9, 29, 58, 62, 64). As the loss of omnipause

**Figure 4.** *p62 immunoreactive neuronal intranuclear inclusions in spared and degenerated brainstem nuclei in Huntington’s disease (HD).* P62 immunopositive neuronal intranuclear inclusions (NI) in well-preserved brainstem nuclei in HD: **A.** pedunculopontine nucleus (PPT), **B.** dorsal raphe nucleus (DR), **C.** locus coeruleus (LC), **D.** motor trigeminal nucleus (MOV), **E.** gigantocellular reticular nucleus (GI), **F.** dorsal motor vagal nucleus (DMV), **G.** hypoglossal nucleus (XII), **H.** external cuneate nucleus (ECU). NI in degenerated brainstem nuclei in HD: **I.** substantia nigra (SN), **J.** pontine nuclei (PN), **K.** reticulotegmental nucleus of the pons (RTTG), **L.** facial nucleus (VII), **M.** superior olive (SO), **N.** medial vestibular nucleus (MV), **O.** lateral vestibular nucleus (LV), **P.** inferior olive (IO) (A, B, F, L, N, O: HD patient 1—Table 1, CAG-repeats in the mutated HD allele: 49; age at HD onset: 33 years; duration of HD: 18 years; Vonsattel grade of striatal atrophy: 4; C, G, H, M: HD patient 7—Table 1, CAG-repeats in the mutated HD allele: 44; age at HD onset: 56 years; duration of HD: 20 years; Vonsattel grade of striatal atrophy: 4; D, I: HD patient 4—Table 1, CAG-repeats in the mutated HD allele: 49; age at HD onset: 53 years; duration of HD: 12 years; Vonsattel grade of striatal atrophy: 4; E, J, K, P: HD patient 6—Table 1, CAG-repeats in the mutated HD allele: 40; age at HD onset: 60 years; duration of HD: 8 years; Vonsattel grade of striatal atrophy: 3). (A–P: p62 immunohistochemistry, counterstaining with aldehyde-fuchsin Darrow red; 100 μm PEG sections).
neurons in the RIP has recently been shown to correlate with slowing of saccades (7, 9, 29, 58, 62, 64), the severe damage to the RIP of our HD patients most likely contributed to the slowing of horizontal saccades observed in our and other HD patients (Table 2) (42, 44, 45, 62, 64). The human premotor area of the excitatory burst neurons for horizontal saccades (EBR) (Figure 2C) was described only some years after the RIP. The EBR is only of about 2.5 mm in width and 2 mm in height and is located

Figure 5. p62 immunoreactive axonal neuronal inclusions in brainstem fiber tracts in Huntington’s disease (HD). P62 immunopositive axonal neuronal inclusions in HD: (A) oculomotor nerve (III), (B) trochlear nerve (IV), (C) pontocerebellar fibers (PCF), (D) PCF, (E) trigeminal nerve (V), (F) facial nerve (VII), (G) trapezoid body (TZ), (H) vestibulocochlear nerve (VIII), (I) inferior cerebellar peduncle (ICP), (J) intermediate reticular zone (IRZ), (K) olivocerebellar fibers (OCF), (L) hypoglossal nerve (XI), (M) hypoglossal nerve (XI), (N) cuneate fascicle (ECU), (O) solitary tract (SOL), (P) dorsal spinocerebellar tract (DST). (A–P: p62/AT270 double immunohistochemistry; 100 μm PEG sections) (A, E, K, N: HD patient 4—Table 1, CAG-repeats in the mutated HD allele: 45; age at HD onset: 53 years; duration of HD: 12 years; Vonsattel grade of striatal atrophy: 4; B, L, P: HD patient 8—Table 1, CAG-repeats in the mutated HD allele: 42; age at HD onset: 55 years; duration of HD: 36 years; Vonsattel grade of striatal atrophy: 2; C, D, F, G, H: HD patient 2—Table 1, CAG-repeats in the mutated HD allele: 45; age at HD onset: 35 years; duration of HD: 26 years; Vonsattel grade of striatal atrophy: 3; I: HD patient 5—Table 1, CAG-repeats in the mutated HD allele: 46; age at HD onset: 40 years; duration of HD: 28 years; Vonsattel grade of striatal atrophy: 3; J, O: HD patient 6—Table 1, CAG-repeats in the mutated HD allele: 40; age at HD onset: 60 years; duration of HD: 8 years; Vonsattel grade of striatal atrophy: 3; M: HD patient 1—Table 1, CAG-repeats in the mutated HD allele: 49; age at HD onset: 33 years; duration of HD: 18 years; Vonsattel grade of striatal atrophy: 4).
in the pontine reticular formation underneath the medial longitudinal fascicle and the internal genu of the facial nerve (7, 9, 29, 62, 64). The neurons of the EBR are essential for the initiation and generation of horizontal saccades (7, 9, 29, 62, 64). Accordingly, damage to the EBR most likely can account for the initiation deficits of horizontal saccades of our and other HD patients (Table 2) (42, 44, 45, 62).

The medial, lateral and superior vestibular nuclei (Figure 3A) via their descending spinal projections are crucial for the maintenance of truncal and postural stability (8, 60, 64). Their involvement in our HD patients may explain as to why our and other HD patients suffered from gait, truncal and postural instability with a tendency to fall (Table 2) (6, 20). Because these vestibular nuclei are important building blocks of the oculomotor circuits subserving the optokinetic nystagmus and vestibulo-ocular reaction (8, 62, 64), damage to these nuclei contributes to the occurrence of this type of impaired eye movements in HD (42, 44, 45).

The reticulotegmental nucleus of the pons (RTTG) (Figure 2A) is a crucial component of the brain neural circuit engaged in the regulation and control of smooth pursuit eye movements (62–64). Thus, together with the lesions in the interconnected fastigial nucleus of the cerebellum (63), damage to the RTTG is well suited to explain why slowed and saccadic smooth pursuits occurred in our and other HD patients (Table 2) (42, 44, 45, 62).

The pontine nuclei and the inferior olive (Figure 3E) represent important building blocks in the pre-cerebellar neuronal circuits and are intimately connected with the cerebellar hemispheres (neo- or pontocerebellum: pontine nuclei and inferior olive), vermal and paravermal regions of the cerebellum (vestibulo- or archicerebellum, spino- or paleocerebellum: inferior olive), as well as associated deep nuclei (ie, fastigial, globose, emboliform and dentate nuclei) (4, 84). Loss of Purkinje cells in the cerebellar cortex and degeneration of nerve cells in all four deep cerebellar nuclei of HD patients (63) in combination with neuronal loss in the pre-cerebellar pontine nuclei and inferior olive are detrimental to the functions accomplished by the pre-cerebellar and cerebellar neural circuits and most likely contributed substantially to the cerebellar disease symptoms observed in our and other HD patients (ie, impairments of rapid alternating movements and fine motor skills, dysarthria, hypotonia, postural instability and ataxia, impaired gait balance, broad-based gait and stance) (Table 2) (34, 49, 63, 85, 86).
The superior olive is located in the caudal pontine tegmentum, embedded into the trapezoid body and involved in the performance of auditory functions, such as perception of the temporal patterns of sounds and analysis of the spatial attributes of sound sources (i.e., location, distance and movement) (Figure 3C) (28, 50). Accordingly, the severe and consistent involvement of the superior olive in our HD patients suggests that impairment of these auditory functions may be among the disease symptoms of HD patients. In view of the striking discrepancy between the involvement of the superior olive in this study and missing clinical reports of auditory impairments in our and other HD patients, additional clinicopathological HD studies are required.

Degeneration of the dopaminergic compact part of the substantia nigra is a characteristic and unifying neuropathological hallmark of all clinical syndromes associated with parkinsonian features (e.g., Parkinson’s disease, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration) (13, 23). Although our study confirms a consistent loss of nerve cells of the compact and reticulate parts of substantia nigra in HD (39, 41, 52), the severity and extent of the neuronal loss in the compact part of the substantia nigra may not suffice to provoke clinically relevant parkinsonian features in adult HD patients (12, 53). This point of view is in agreement with the clinical experience that parkinsonian extrapyramidal motor features (e.g., rigidity) only emerge in juvenile onset HD patients (82, 85, 86).

Neuronal intranuclear and axonal inclusions and their possible significance to the neurodegenerative process of HD

The aggregation of the disease protein huntingtin into NI bodies is a well-known neuropathological feature of HD (3, 17, 19, 21, 22, 31, 36, 47, 48). NI are most frequent in the degenerated striatum and cerebral neo- and allocortex and may contain components of the cellular protein quality control machinery responsible for removing and degrading structurally abnormal, misfolded and ubiquitin-tagged proteins (i.e., ubiquitin, chaperones, proteasome subunits) (2, 17, 19, 21, 22, 30, 31, 47, 48, 55, 65, 74, 80). It is still an open question whether NI are toxic to or protective for affected nerve cells or merely represent pathognomonic morphological hallmarks of HD and currently no idea is in existence with respect to the possible mechanisms in which way they may contribute to damage of affected nerve cells or facilitate their survival (17, 19, 31, 36, 65, 74, 80). In this study, we observed NI in neurons of all brainstem nuclei of HD patients investigated, irrespective of whether they showed signs of degeneration or appeared unaffected, and failed to establish a correlation between the distribution of NI and the pattern of neuronal loss in the brainstem. Evidently, our correlative post-mortem approach cannot provide a conclusive answer to the question whether the NI play a causal role in the cascades of pathological events leading to nerve cell loss. However, our study indicates that NI are to be considered as pathognomonic morphological hallmarks of HD.

In addition, NI neuropathological studies also described the occurrence of neuropil (i.e., neuritic or axonal aggregates or swellings) in select brain gray and white matters of HD patients (e.g., striatum, cerebral neocortex, internal capsule, cerebral peduncle) (17, 22, 31, 36, 47, 65, 74). Our study represents the first systematic analysis of axonal protein aggregates in fiber tracts of a...
coherent brain region of HD patients (ie, brainstem) and for the first time demonstrates that axonal protein aggregations are a consistent and widespread feature of brainstem pathology in HD. Accordingly, together with SCA3, HD has now been recognized as the second polyglutamine disease associated with the presence of axonal protein aggregates (69, 70).

The composition of the intra-axonal inclusions observed here shares many biological similarities with that of the NI. Axonal inclusions in HD can be immunostained with the anti-polyglutamine antibody 1C2 and along with the pathologically altered form of the disease protein huntingtin with elongated polyglutamin tract axonal inclusions in HD also contain the degradation-related proteins p62 and ubiquitin. Together with ubiquitin, p62 plays a central role in the highly dynamic pathways that remove and degrade short-lived or aberrantly structured proteins, thus preventing their aggregation (30, 55). Their presence in intra-axonal aggregates of HD patients suggests an involvement of the ubiquitin-proteasome pathway in the HD pathogenesis (10, 30, 84) and points to defense mechanisms of affected nerve cells that attempt to reduce levels of mutant and misfolded huntingtin (10, 17). The presence of ubiquitin and p62 in axonal aggregates also reflects a decreased or compromised activity of the ubiquitin-proteasome pathway or its overload in HD causing aggregate formation (10, 30, 64, 80). Uprolepin and enhancement of proteasome activity with drugs is considered as a promising therapeutic strategy to reduce the pathological levels of the polyglutamine protein huntingtin and the pathological consequences associated with this aggregation in affected nerve cells (10, 30, 55).

Several disease models have proposed the occurrence and a causative feature of axonal transport deficits in HD (11, 21). Although the pathological mechanisms leading to axonal transport deficits in HD remain unclear, it has been suggested that intra-axonal transport deficits in HD may result from a physical block caused by intra-axonal protein aggregation formation (11, 21). In the present study, we could indeed observe intra-axonal protein aggregates in the brainstem fiber tracts of the HD patients studied, irrespective of the length, caliber or myelinization of the affected axons. In view of their size, diameter and insolubility, these intra-axonal aggregations are likely to physically block and to perturbate anterograde and retrograde axonal transport processes (17, 21, 22, 31, 46, 65). The failure of anterograde transport mechanisms can impair movement of protein complexes, synaptic vesicles and neuronal organelles, can lead to structural changes in axons and accumulations of vesicles and organelles (eg, mitochondria), and can result in synaptic and mitochondrial dysfunction which are detrimental to ATP production and energy metabolism further impairing axonal transport processes (11, 17, 21, 31, 46, 63, 65). In view of the current uncertainties regarding the mechanisms of nerve cell death in HD and the possible consequences of intra-axonal aggregates for neuronal viability or demise, we think it is justified and worthwhile to perform additional HD studies aimed to (i) reconstruct the spatial and temporal evolution of these axonal aggregates and their association with the development of neurodegeneration; and (ii) to investigate the presence of axonal accumulations of cellular organelles, vesicles and proteins in affected axons. These future studies may help to decipher the pathophysiological and pathobiochemical mechanisms of the neurodegenerative process of HD and represent a step forward on the road to a causative and disease modifying therapy for this severe and disabling human neuropsychiatric disease.

ACKNOWLEDGMENTS

This study was supported by grants from the Dr. Senckenbergische Stiftung (Frankfurt/Main, Germany), the Deutsche Huntington Hilfe e.V. and NIH R01NS038712 to HLP. The skillful assistance of D. von Meltzer (secretary) is thankfully acknowledged.

REFERENCES


spino cerebellar ataxia type 3 (SCA3) patients and its possible